Graphene oxide as a chemosensitizer: Diverted autophagic flux, enhanced nuclear import, elevated necrosis and improved antitumor effects

Biomaterials

Volumn 40, Issue , 2015, Pages 12-22

  Chen, Guan Yu ^a   Meng, Chia Le ^a   Lin, Kuan Chen ^a   Tuan, Hsing Yu ^a   Yang, Hong Jie ^a   Chen, Chiu Ling ^a   Li, Kuei Chang ^a   Chiang, Chi Shiun ^a   Hu, Yu Chen ^a  

^a NATIONAL TSING HUA UNIVERSITY   (Taiwan)

Author keywords

Autophagy; Chemoresistance; Cisplatin; Graphene oxide; Necrosis; Nuclear import

Indexed keywords

CHEMOTHERAPY; DISEASES; GRAPHENE; GRAPHENE OXIDE; MAMMALS; NANOSTRUCTURED MATERIALS;

AUTOPHAGY; CHEMORESISTANCE; CIS-PLATIN; NECROSIS; NUCLEAR IMPORT;

CELL DEATH;

ANTINEOPLASTIC AGENT; CASPASE 3; CISPLATIN; DOXORUBICIN; GRAPHENE OXIDE; HIGH MOBILITY GROUP B1 PROTEIN; IRINOTECAN; KARYOPHERIN ALPHA; KARYOPHERIN BETA; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 2; OXALIPLATIN; PROTEIN P62; GRAPHITE; MAP1LC3 PROTEIN, MOUSE; MICROTUBULE ASSOCIATED PROTEIN; OXIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; AUTOLYSOSOME; AUTOPHAGOSOME; AUTOPHAGY; CD4+ T LYMPHOCYTE; CELL DEATH; CELL INFILTRATION; CELL KILLING; CELL NUCLEUS; CELL VIABILITY; CHEMOSENSITIZATION; COLORECTAL CARCINOMA; CONTROLLED STUDY; CYTOSOL; CYTOTOXICITY; DENDRITIC CELL; DRUG POTENTIATION; IMMUNOCOMPETENT CELL; MACROPHAGE; MALE; MOUSE; NONHUMAN; NUCLEAR IMPORT; PROTEIN LOCALIZATION; TUMOR GROWTH; TUMOR VOLUME; ACTIVE TRANSPORT; ANIMAL; BAGG ALBINO MOUSE; COLONIC NEOPLASMS; DRUG EFFECTS; METABOLISM; NECROSIS; PATHOLOGY; TUMOR CELL LINE;

MUS;

ACTIVE TRANSPORT, CELL NUCLEUS; ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AUTOPHAGY; CELL LINE, TUMOR; CELL NUCLEUS; CISPLATIN; COLONIC NEOPLASMS; GRAPHITE; MICE, INBRED BALB C; MICROTUBULE-ASSOCIATED PROTEINS; NECROSIS; OXIDES;

EID: 84919683267     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2014.11.034     Document Type: Article

References (50)

1. Levine B., Mizushima N., Virgin H.W. Autophagy in immunity and inflammation. Nature 2011, 469:323-335.
2. Yang Z.J., Chee C.E., Huang S., Sinicrope F.A. The role of autophagy in cancer: therapeutic implications. Mol Cancer Ther 2011, 10:1533-1541.
3. Fullgrabe J., Klionsky D.J., Joseph B. The return of the nucleus: transcriptional and epigenetic control of autophagy. Nat Rev Mol Cell Biol 2014, 15:65-74.
4. Gewirtz D.A. The four faces of autophagy: implications for cancer therapy. Cancer Res 2014, 74:647-651.
5. Chen G.Y., Pang D.W.P., Hwang S.M., Tuan H.Y., Hu Y.C. Agraphene-based platform for induced pluripotent stem cells culture and differentiation. Biomaterials 2012, 33:418-427.
6. Zhang L., Lu Z., Zhao Q., Huang J., Shen H., Zhang Z. Enhanced chemotherapy efficacy by sequential delivery of siRNA and anticancer drugs using PEI-grafted graphene oxide. Small 2011, 7:460-464.
7. Zhang L., Xia J., Zhao Q., Liu L., Zhang Z. Functional graphene oxide as a nanocarrier for controlled loading and targeted delivery of mixed anticancer drugs. Small 2010, 6:537-544.
8. Yang K., Wan J., Zhang S., Tian B., Zhang Y., Liu Z. The influence of surface chemistry and size of nanoscale graphene oxide on photothermal therapy of cancer using ultra-low laser power. Biomaterials 2012, 33:2206-2214.
9. Tao Y., Ju E., Ren J., Qu X. Immunostimulatory oligonucleotides-loaded cationic graphene oxide with photothermally enhanced immunogenicity for photothermal/immune cancer therapy. Biomaterials 2014, 35:9963-9971.
10. Chen G.-Y., Yang H.-J., Lu C.-H., Chao Y.-C., Hwang S.-M., Chen C.-L., et al. Simultaneous induction of autophagy and toll-like receptor signaling pathways by graphene oxide. Biomaterials 2012, 33:6559-6569.
11. Chen G.Y., Chen C.L., Tuan H.Y., Yuan P.X., Li K.C., Yang H.J., et al. Graphene oxide triggers toll-like receptors/autophagy responses invitro and inhibits tumor growth invivo. Adv Healthc Mater 2014, 3:1486-1495.
12. Tournigand C., Andre T., Bonnetain F., Chibaudel B., Lledo G., Hickish T., et al. Adjuvant therapy with fluorouracil and oxaliplatin in stage II and elderly patients (between ages 70 and 75 years) with colon cancer: subgroup analyses of the Multicenter International Study of Oxaliplatin, Fluorouracil, and Leucovorin in the Adjuvant Treatment of Colon Cancer trial. JClin Oncol 2012, 30:3353-3360.
13. Choi C.K., Chan R.T., Tung S.Y., Lui L., Siu S., Au G.K., et al. Efficacy of combination chemotherapy with irinotecan (CPT-11) plus capecitabine in patients with metastatic or advanced colorectal carcinoma-a dual-centre phase II study: the MAC-6. Clin Oncol (R Coll Radiol) 2008, 20:168-175.
14. Tesniere A., Schlemmer F., Boige V., Kepp O., Martins I., Ghiringhelli F., et al. Immunogenic death of colon cancer cells treated with oxaliplatin. Oncogene 2010, 29:482-491.
15. Tyedmers J., Mogk A., Bukau B. Cellular strategies for controlling protein aggregation. Nat Rev Mol Cell Biol 2010, 11:777-788.
16. Peracchio C., Alabiso O., Valente G., Isidoro C. Involvement of autophagy in ovarian cancer: a working hypothesis. JOvarian Res 2012, 5:22.
17. Zhang Q., Yang W., Man N., Zheng F., Shen Y., Sun K., et al. Autophagy-mediated chemosensitization in cancer cells by fullerene C60 nanocrystal. Autophagy 2009, 5:1107-1117.
18. Wang X., Zhong S.H., He Y., Song G.W. Agraphene oxide-rhodamine 6G nanocomposite as turn-on fluorescence probe for selective detection of DNA. Anal Methods 2012, 4:360-362.
19. Yang H.P., Hu H.L., Ni Z.H., Poh C.K., Cong C.X., Lin J.Y., et al. Comparison of surface-enhanced Raman scattering on graphene oxide, reduced graphene oxide and graphene surfaces. Carbon 2013, 62:422-429.
20. Wan B., Wang Z.X., Lv Q.Y., Dong P.X., Zhao L.X., Yang Y., et al. Single-walled carbon nanotubes and graphene oxides induce autophagosome accumulation and lysosome impairment in primarily cultured murine peritoneal macrophages. Toxicol Lett 2013, 221:118-127.
21. Uchino H., Matsumura Y., Negishi T., Koizumi F., Hayashi T., Honda T., et al. Cisplatin-incorporating polymeric micelles (NC-6004) can reduce nephrotoxicity and neurotoxicity of cisplatin in rats. Br J Cancer 2005, 93:678-687.
22. Zhang H., Zhang S., He H., Zhao W., Ren K., Chen J., et al. RasGAP-derived peptide 38GAP potentiates the cytotoxicity of cisplatin through inhibitions of Akt, ERK and NF-kappaB in colon carcinoma HCT116 cells. Cancer Lett 2011, 308:62-70.
23. Yang H.N., Rivera Z., Jube S., Nasu M., Bertino P., Goparaju C., et al. Programmed necrosis induced by asbestos in human mesothelial cells causes high-mobility group box 1 protein release and resultant inflammation. Proc Natl Acad Sci 2010, 107:12611-12616.
24. Eisenberg T., Knauer H., Schauer A., Buttner S., Ruckenstuhl C., Carmona-Gutierrez D., et al. Induction of autophagy by spermidine promotes longevity. Nat Cell Biol 2009, 11:1305-1314.
25. Raucci A., Palumbo R., Bianchi M.E. HMGB1: a signal of necrosis. Autoimmunity 2007, 40:285-289.
26. Wagstaff K.M., Sivakumaran H., Heaton S.M., Harrich D., Jans D.A. Ivermectin is a specific inhibitor of importin alpha/beta-mediated nuclear import able to inhibit replication of HIV-1 and dengue virus. Biochem J 2012, 443:851-856.
27. Cloonan S.M., Williams D.C. The antidepressants maprotiline and fluoxetine induce Type II autophagic cell death in drug-resistant Burkitt's lymphoma. Int J Cancer 2011, 128:1712-1723.
28. Klionsky D.J., Abdalla F.C., Abeliovich H., Abraham R.T., Acevedo-Arozena A., Adeli K., et al. Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy 2012, 8:445-544.
29. Badding M.A., Lapek J.D., Friedman A.E., Dean D.A. Proteomic and functional analyses of protein-DNA complexes during gene transfer. Mol Ther 2013, 21:775-785.
30. Bampton E.T.W., Goemans C.G., Niranjan D., Mizushima N., Tolkovsky A.M. The dynamics of autophagy visualized in live cells - from autophagosome formation to fusion with endo/lysosomes. Autophagy 2005, 1:23-36.
31. Cieehomska I.A., Tolkovsky A.M. Non-autophagic GFP-LC3 puncta induced by saponin and other detergents. Autophagy 2007, 3:586-590.
32. Kochl R., Hu X.W., Chan E.Y., Tooze S.A. Microtubules facilitate autophagosome formation and fusion of autophagosomes with endosomes. Traffic 2006, 7:129-145.
33. Kuma A., Matsui M., Mizushima N. LC3, an autophagosome marker, can be incorporated into protein aggregates independent of autophagy. Autophagy 2007, 3:323-328.
34. Drake K.R., Kang M., Kenworthy A.K. Nucleocytoplasmic distribution and dynamics of the autophagosome marker EGFP-LC3. Plos One 2010, 5:e9806.
35. Martinez-Lopez N., Athonvarangkul D., Mishall P., Sahu S., Singh R. Autophagy proteins regulate ERK phosphorylation. Nat Commun 2013, 4:2799.
36. Florea A.-M., Büsselberg D. Cisplatin as an anti-tumor drug: cellular mechanisms of activity, drug resistance and induced side effects. Cancers 2011, 3:1351-1371.
37. Galluzzi L., Vitale I., Michels J., Brenner C., Szabadkai G., Harel-Bellan A., et al. Systems biology of cisplatin resistance: past, present and future. Cell Death Dis 2014, 5:e1257.
38. Akaboshi M., Kawai K., Ujeno Y., Takada S., Miyahara T. Binding characteristics of (-)-(R)-2-aminomethylpyrrolidine(1,1-cyclobutanedicarboxylato)-2-platin um(II) to DNA, RNA and protein molecules in HeLa cells and its lethal effect: comparison with cis- and trans-diamminedichloroplatinums(II). Jpn J Cancer Res 1994, 85:106-111.
39. Safaei R., Larson B.J., Cheng T.C., Gibson M.A., Otani S., Naerdemann W., et al. Abnormal lysosomal trafficking and enhanced exosomal export of cisplatin in drug-resistant human ovarian carcinoma cells. Mol Cancer Ther 2005, 4:1595-1604.
40. Sancho-Martínez S.M., Prieto-García L., Prieto M., López-Novoa J.M., López-Hernández F.J. Subcellular targets of cisplatin cytotoxicity: an integrated view. Pharmacol Ther 2012, 136:35-55.
41. Yu H., Su J., Xu Y., Kang J.S., Li H.Y., Zhang L., et al. p62/SQSTM1 involved in cisplatin resistance in human ovarian cancer cells by clearing ubiquitinated proteins. Eur J Cancer 2011, 47:1585-1594.
42. Ren J.H., He W.S., Nong L., Zhu Q.Y., Hu K., Zhang R.G., et al. Acquired cisplatin resistance in human lung adenocarcinoma cells is associated with enhanced autophagy. Cancer Biother Radiopharm 2010, 25:75-80.
43. Gonzalez V.M., Fuertes M.A., Alonso C., Perez J.M. Is cisplatin-induced cell death always produced by apoptosis?. Mol Pharmacol 2001, 59:657-663.
44. Cepeda V., Fuertes M.A., Castilla J., Alonso C., Quevedo C., Perez J.M. Biochemical mechanisms of cisplatin cytotoxicity. Anticancer Agents Med Chem 2007, 7:3-18.
45. Qu G., Liu S., Zhang S., Wang L., Wang X., Sun B., et al. Graphene oxide induces toll-like receptor 4 (TLR4)-dependent necrosis in macrophages. ACS Nano 2013, 7:5732-5745.
46. Krysko D.V., Garg A.D., Kaczmarek A., Krysko O., Agostinis P., Vandenabeele P. Immunogenic cell death and DAMPs in cancer therapy. Nat Rev Cancer 2012, 12:860-875.
47. Garg A.D., Krysko D.V., Verfaillie T., Kaczmarek A., Ferreira G.B., Marysael T., et al. Anovel pathway combining calreticulin exposure and ATP secretion in immunogenic cancer cell death. EMBO J 2012, 31:1062-1079.
48. Michaud M., Martins I., Sukkurwala A.Q., Adjemian S., Ma Y., Pellegatti P., et al. Autophagy-dependent anticancer immune responses induced by chemotherapeutic agents in mice. Science 2011, 334:1573-1577.
49. Yue H., Wei W., Yue Z., Wang B., Luo N., Gao Y., et al. The role of the lateral dimension of graphene oxide in the regulation of cellular responses. Biomaterials 2012, 33:4013-4021.
50. Zong D., Haag P., Yakymovych I., Lewensohn R., Viktorsson K. Chemosensitization by phenothiazines in human lung cancer cells: impaired resolution of γH2AX and increased oxidative stress elicit apoptosis associated with lysosomal expansion and intense vacuolation. Cell Death Dis 2011, 2:e181.